Sign in Sign up for free

Last updated: 10 February 2020 at 5:23pm EST

Alan Buckler Net Worth



Alan Buckler biography

Dr. Alan J. Buckler, Ph.D. is Chief Scientific Officer of the company since November 2016. Prior to joining us, Dr. Buckler served as Vice President, Cell and Protein Sciences, at Biogen Inc. from 2014 to 2016. From 2005 to 2014, Dr. Buckler served as Director, Developmental and Molecular Pathways in the Novartis Institutes for Biomedical Research. Prior to Novartis, Dr. Buckler served as the Chief Scientific Officer of Ardais Corporation from 1999 to 2004 and as Vice President of Molecular Genetics at Sequana Therapeutics/Axys Pharmaceuticals from 1996 to 1999. Prior to joining the private sector, Dr. Buckler served on the Neurology faculty of Massachusetts General Hospital and Harvard Medical School from 1991 to 1996. Dr. Buckler received his Ph.D. in Microbiology from the Boston University School of Medicine, and completed his post-doctoral training at the Center for Cancer Research, Massachusetts Institute of Technology. He also holds an A.B. in Biology from the University of Chicago.

What is the salary of Alan Buckler?

As the Chief Scientific Officer of Scholar Rock Corp, the total compensation of Alan Buckler at Scholar Rock Corp is $1,093,970. There are 2 executives at Scholar Rock Corp getting paid more, with Dr. Nagesh K. Mahanthappa MBA, Ph.D. having the highest compensation of $1,372,681.



How old is Alan Buckler?

Alan Buckler is 60, he's been the Chief Scientific Officer of Scholar Rock Corp since 2016. There are 1 older and 12 younger executives at Scholar Rock Corp. The oldest executive at Scholar Rock Holding Corp is Michael Gilman, 65, who is the Independent Director.

What's Alan Buckler's mailing address?

Alan's mailing address filed with the SEC is 620 MEMORIAL DRIVE, SECOND FLOOR, , CAMBRIDGE, MA, 02139.

Insiders trading at Scholar Rock Corp

Over the last 6 years, insiders at Scholar Rock Corp have traded over $8,613,447 worth of Scholar Rock Corp stock and bought 8,895,194 units worth $64,726,758 . The most active insiders traders include Timothy A Springer, Srinivas Akkaraju, and Amir Nashat. On average, Scholar Rock Corp executives and independent directors trade stock every 55 days with the average trade being worth of $1,953,616. The most recent stock trade was executed by Caryn Parlavecchio on 16 August 2024, trading 1,451 units of SRRK stock currently worth $13,538.



What does Scholar Rock Corp do?

scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s



What does Scholar Rock Corp's logo look like?

Scholar Rock Holding Corp logo

Scholar Rock Corp executives and stock owners

Scholar Rock Corp executives and other stock owners filed with the SEC include: